Cargando…

The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials

Background: With the development of the sentinel node technique in early-stage cervical cancer, it is imperative to define the clinical significance of micrometastases (MICs) and isolated tumor cells (ITCs). Methods: We included all patients who participated in the Senticol 1 and Senticol 2 studies....

Descripción completa

Detalles Bibliográficos
Autores principales: Guani, Benedetta, Balaya, Vincent, Magaud, Laurent, Lecuru, Fabrice, Mathevet, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281258/
https://www.ncbi.nlm.nih.gov/pubmed/32344814
http://dx.doi.org/10.3390/cancers12051061
_version_ 1783543881170681856
author Guani, Benedetta
Balaya, Vincent
Magaud, Laurent
Lecuru, Fabrice
Mathevet, Patrice
author_facet Guani, Benedetta
Balaya, Vincent
Magaud, Laurent
Lecuru, Fabrice
Mathevet, Patrice
author_sort Guani, Benedetta
collection PubMed
description Background: With the development of the sentinel node technique in early-stage cervical cancer, it is imperative to define the clinical significance of micrometastases (MICs) and isolated tumor cells (ITCs). Methods: We included all patients who participated in the Senticol 1 and Senticol 2 studies. We analyzed the factors associated with the presence of low-volume metastasis, the oncological outcomes of patients with MIC and ITC and the correlation of recurrences and risk factors. Results: Twenty-four patients (7.5%) had low-volume metastasis. The risk factors associated with the presence of low-volume metastasis were a higher stage (p = 0.02) and major stromal invasion (p = 0.01) in the univariate analysis. The maximum specificity and sensitivity were found at a cutoff of 8 mm of stromal invasion. In multivariate analysis, the higher stage (p = 0.02) and the positive lymphovascular space invasion (p = 0.02) were significantly associated with the MIC and ITC. Patients with low-volume metastasis had similar disease-free survival (DFS) (92.7%) to node-negative patients (93.6%). The addition of adjuvant treatment in presence of low-volume metastasis did not modify the DFS. Conclusions: These results confirm our previous analysis of Senticol 1: the presence of low-volume metastasis did not decrease the DFS in early-stage cervical cancer patients.
format Online
Article
Text
id pubmed-7281258
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72812582020-06-15 The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials Guani, Benedetta Balaya, Vincent Magaud, Laurent Lecuru, Fabrice Mathevet, Patrice Cancers (Basel) Article Background: With the development of the sentinel node technique in early-stage cervical cancer, it is imperative to define the clinical significance of micrometastases (MICs) and isolated tumor cells (ITCs). Methods: We included all patients who participated in the Senticol 1 and Senticol 2 studies. We analyzed the factors associated with the presence of low-volume metastasis, the oncological outcomes of patients with MIC and ITC and the correlation of recurrences and risk factors. Results: Twenty-four patients (7.5%) had low-volume metastasis. The risk factors associated with the presence of low-volume metastasis were a higher stage (p = 0.02) and major stromal invasion (p = 0.01) in the univariate analysis. The maximum specificity and sensitivity were found at a cutoff of 8 mm of stromal invasion. In multivariate analysis, the higher stage (p = 0.02) and the positive lymphovascular space invasion (p = 0.02) were significantly associated with the MIC and ITC. Patients with low-volume metastasis had similar disease-free survival (DFS) (92.7%) to node-negative patients (93.6%). The addition of adjuvant treatment in presence of low-volume metastasis did not modify the DFS. Conclusions: These results confirm our previous analysis of Senticol 1: the presence of low-volume metastasis did not decrease the DFS in early-stage cervical cancer patients. MDPI 2020-04-25 /pmc/articles/PMC7281258/ /pubmed/32344814 http://dx.doi.org/10.3390/cancers12051061 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guani, Benedetta
Balaya, Vincent
Magaud, Laurent
Lecuru, Fabrice
Mathevet, Patrice
The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials
title The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials
title_full The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials
title_fullStr The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials
title_full_unstemmed The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials
title_short The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials
title_sort clinical impact of low-volume lymph nodal metastases in early-stage cervical cancer: the senticol 1 and senticol 2 trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281258/
https://www.ncbi.nlm.nih.gov/pubmed/32344814
http://dx.doi.org/10.3390/cancers12051061
work_keys_str_mv AT guanibenedetta theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT balayavincent theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT magaudlaurent theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT lecurufabrice theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT mathevetpatrice theclinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT guanibenedetta clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT balayavincent clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT magaudlaurent clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT lecurufabrice clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials
AT mathevetpatrice clinicalimpactoflowvolumelymphnodalmetastasesinearlystagecervicalcancerthesenticol1andsenticol2trials